Abstract: Provided herein are compositions and methods for modifying a predetermined nucleic acid sequence. A programmable nucleoprotein molecular complex containing a polypeptide moiety and a specificity conferring nucleic acid (SCNA) which assembles in-vivo, in a target cell, and is capable of interacting with the predetermined target nucleic acid sequence is provided. The programmable nucleoprotein molecular complex is capable of specifically modifying and/or editing a target site within the target nucleic acid sequence and/or modifying the function of the target nucleic acid sequence.
Type:
Application
Filed:
May 15, 2023
Publication date:
May 9, 2024
Applicant:
TARGETGENE BIOTECHNOLOGIES LTD.
Inventors:
Yoel Moshe SHIBOLETH, Dan Michael WEINTHAL
Abstract: Provided herein are compositions and methods for modifying a predetermined nucleic acid sequence. A programmable nucleoprotein molecular complex containing a polypeptide moiety and a specificity conferring nucleic acid (SCNA) which assembles in-vivo, in a target cell, and is capable of interacting with the predetermined target nucleic acid sequence is provided. The programmable nucleoprotein molecular complex is capable of specifically modifying and/or editing a target site within the target nucleic acid sequence and/or modifying the function of the target nucleic acid sequence.
Type:
Grant
Filed:
March 3, 2017
Date of Patent:
July 4, 2023
Assignee:
TARGETGENE BIOTECHNOLOGIES LTD.
Inventors:
Yoel Moshe Shiboleth, Dan Michael Weinthal
Abstract: Provided herein are compositions and methods for modifying a predetermined nucleic acid sequence. A programmable nucleoprotein molecular complex containing a polypeptide moiety and a specificity conferring nucleic acid (SCNA) which assembles in-vivo, in a target cell, and is capable of interacting with the predetermined target nucleic acid sequence is provided. The programmable nucleoprotein molecular complex is capable of specifically modifying and/or editing a target site within the target nucleic acid sequence and/or modifying the function of the target nucleic acid sequence.
Type:
Grant
Filed:
December 16, 2012
Date of Patent:
October 4, 2022
Assignee:
Targetgene Biotechnologies Ltd.
Inventors:
Yoel Moshe Shiboleth, Dan Michael Weinthal
Abstract: Provided herein are compositions and methods for modifying a predetermined nucleic acid sequence. A programmable nucleoprotein molecular complex containing a polypeptide moiety and a specificity conferring nucleic acid (SCNA) which assembles in-vivo, in a target cell, and is capable of interacting with the predetermined target nucleic acid sequence is provided. The programmable nucleoprotein molecular complex is capable of specifically modifying and/or editing a target site within the target nucleic acid sequence and/or modifying the function of the target nucleic acid sequence.
Type:
Grant
Filed:
March 3, 2017
Date of Patent:
March 22, 2022
Assignee:
TARGETGENE BIOTECHNOLOGIES LTD.
Inventors:
Yoel Moshe Shiboleth, Dan Michael Weinthal
Abstract: Provided herein are compositions and methods for modifying a predetermined nucleic acid sequence. A programmable nucleoprotein molecular complex containing a polypeptide moiety and a specificity conferring nucleic acid (SCNA) which assembles in-vivo, in a target cell, and is capable of interacting with the predetermined target nucleic acid sequence is provided. The programmable nucleoprotein molecular complex is capable of specifically modifying and/or editing a target site within the target nucleic acid sequence and/or modifying the function of the target nucleic acid sequence.
Type:
Grant
Filed:
April 28, 2017
Date of Patent:
March 5, 2019
Assignee:
TARGETGENE BIOTECHNOLOGIES LTD
Inventors:
Yoel Moshe Shiboleth, Dan Michael Weinthal
Abstract: Provided herein are compositions and methods for modifying a predetermined nucleic acid sequence. A programmable nucleoprotein molecular complex containing a polypeptide moiety and a specificity conferring nucleic acid (SCNA) which assembles in-vivo, in a target cell, and is capable of interacting with the predetermined target nucleic acid sequence is provided. The programmable nucleoprotein molecular complex is capable of specifically modifying and/or editing a target site within the target nucleic acid sequence and/or modifying the function of the target nucleic acid sequence.
Type:
Application
Filed:
April 28, 2017
Publication date:
August 17, 2017
Applicant:
TARGETGENE BIOTECHNOLOGIES LTD.
Inventors:
Yoel Moshe SHIBOLETH, Dan Michael WEINTHAL